soul trial oral semaglutide cardiovascular outcomes 2024 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Ongoing #GLP1 -RA Trials soul semaglutide Oral and Cardiovascular

People with diabetes are more prone to yeast infections, so those using semaglutide for diabetes management may have a higher baseline risk compared to those using it strictly for weight loss

Days five through seven (the taper) As blood levels decline toward the end of the weekly cycle, some people notice a gradual return of appetite

It's hormones working against them

GLP-1 medications may cause side effects including nausea, vomiting, and diarrhea

Daily target: 1.2-2.0g protein per kg body weight

This suggests that the medication helps maintain weight loss but does not permanently change underlying biological drivers of weight gain